Fecal Calprotectin Predicts Complete Mucosal Healing in UC
By LabMedica International staff writers Posted on 13 Nov 2017 |

Image: The rapid Quantum Blue Fecal Calprotectin lateral flow test (Photo courtesy of Bühlmann Laboratories).
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by a disease course involving relapses and remissions. Historically, clinical remission was the major treatment target for patients with UC.
The use of repeated endoscopy to verify mucosal healing (MH) is invasive, inconvenient, and expensive, and may present a risk of significant complications such as colonic perforation. Therefore, noninvasive surrogate markers indicating endoscopic healing have been investigated to replace the repeated endoscopic procedures.
Scientists at the University of Ulsan College of Medicine (Seoul, Republic of Korea) collected 181 fecal samples from 181 consecutive UC patients between April 2015 and September 2016. Collected data included birth date, sex, date of UC diagnosis, family history of IBD, smoking status, maximum disease extent, and medications. The laboratory test results, partial Mayo Score (pMS), and colonoscopic imaging findings at Fecal Calprotectin (FC) level measurement were retrospectively reviewed.
FC levels were measured using the Quantum Blue Calprotectin rapid test (Bühlmann Laboratories AG, Schönenbuch, Switzerland), and high-range kit measuring 100–1,800 mg/kg was used. The following laboratory parameters were recorded at the time of FC level measurement: complete blood cell count on the XE-2100 (Sysmex Corporation, Kobe, Japan), including white blood cell count, hemoglobin level, hematocrit value, and platelet count; erythrocyte sedimentation rate (ESR); and serum chemistry values on the Cobas 8000 modular analyzer (Roche Diagnostics, Basel, Switzerland), and the AU5800 (Beckman Coulter, Brea, CA, USA), including C-reactive protein (CRP) and albumin levels.
The investigators found that among the biochemical markers, FC levels exhibited significant correlations with the CRP and serum albumin. The other laboratory values including white blood cell count, hematocrit values, platelet and ESR exhibited weaker correlations with the FC levels, as compared to both the CRP and serum albumin levels. The FC cut-off level of 187.0 mg/kg indicated complete mucosal healing with a sensitivity and specificity of 0.857 and 0.891, respectively.
The authors concluded that the FC level is significantly correlated with the clinical disease activity index, endoscopic indices, and serum inflammatory biomarkers in a Korean UC cohort. FC is highly predictive of complete mucosal healing in UC. UC endoscopic index of severity (UCEIS) exhibits a stronger correlation with the FC level; as compared to the Mayo endoscopic subscore (MES). Thus, FC could be used as a reliable noninvasive indicator for evaluating disease activity and mucosal healing in UC. The study was published on October 23, 2017, in the journal BMC Gastroenterology.
The use of repeated endoscopy to verify mucosal healing (MH) is invasive, inconvenient, and expensive, and may present a risk of significant complications such as colonic perforation. Therefore, noninvasive surrogate markers indicating endoscopic healing have been investigated to replace the repeated endoscopic procedures.
Scientists at the University of Ulsan College of Medicine (Seoul, Republic of Korea) collected 181 fecal samples from 181 consecutive UC patients between April 2015 and September 2016. Collected data included birth date, sex, date of UC diagnosis, family history of IBD, smoking status, maximum disease extent, and medications. The laboratory test results, partial Mayo Score (pMS), and colonoscopic imaging findings at Fecal Calprotectin (FC) level measurement were retrospectively reviewed.
FC levels were measured using the Quantum Blue Calprotectin rapid test (Bühlmann Laboratories AG, Schönenbuch, Switzerland), and high-range kit measuring 100–1,800 mg/kg was used. The following laboratory parameters were recorded at the time of FC level measurement: complete blood cell count on the XE-2100 (Sysmex Corporation, Kobe, Japan), including white blood cell count, hemoglobin level, hematocrit value, and platelet count; erythrocyte sedimentation rate (ESR); and serum chemistry values on the Cobas 8000 modular analyzer (Roche Diagnostics, Basel, Switzerland), and the AU5800 (Beckman Coulter, Brea, CA, USA), including C-reactive protein (CRP) and albumin levels.
The investigators found that among the biochemical markers, FC levels exhibited significant correlations with the CRP and serum albumin. The other laboratory values including white blood cell count, hematocrit values, platelet and ESR exhibited weaker correlations with the FC levels, as compared to both the CRP and serum albumin levels. The FC cut-off level of 187.0 mg/kg indicated complete mucosal healing with a sensitivity and specificity of 0.857 and 0.891, respectively.
The authors concluded that the FC level is significantly correlated with the clinical disease activity index, endoscopic indices, and serum inflammatory biomarkers in a Korean UC cohort. FC is highly predictive of complete mucosal healing in UC. UC endoscopic index of severity (UCEIS) exhibits a stronger correlation with the FC level; as compared to the Mayo endoscopic subscore (MES). Thus, FC could be used as a reliable noninvasive indicator for evaluating disease activity and mucosal healing in UC. The study was published on October 23, 2017, in the journal BMC Gastroenterology.
Latest Clinical Chem. News
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Channels
Molecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more